BANK OF MONTREAL /CAN/ - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 176 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2016. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2023$229,083
-95.2%
4,739
-95.7%
0.00%
-100.0%
Q3 2022$4,788,000
+63.6%
111,336
+176.1%
0.00%
+100.0%
Q1 2022$2,927,000
+4.7%
40,319
+22.7%
0.00%0.0%
Q4 2021$2,795,000
-3.4%
32,850
-1.2%
0.00%0.0%
Q3 2021$2,892,000
-8.6%
33,259
+1.6%
0.00%
-50.0%
Q2 2021$3,164,000
+632.4%
32,739
+706.2%
0.00%
Q1 2021$432,000
-72.2%
4,061
-62.9%
0.00%
-100.0%
Q4 2020$1,552,000
+344.7%
10,950
+178.8%
0.00%
Q3 2020$349,000
-31.4%
3,928
-32.2%
0.00%
Q2 2020$509,000
+1442.4%
5,790
+773.3%
0.00%
Q1 2020$33,000
-89.1%
663
-90.6%
0.00%
Q4 2019$302,000
+37.3%
7,059
+37.0%
0.00%
Q3 2019$220,000
-30.8%
5,153
+2.8%
0.00%
Q2 2019$318,000
+715.4%
5,014
+795.4%
0.00%
Q1 2019$39,000
-17.0%
560
-48.1%
0.00%
Q4 2018$47,000
+14.6%
1,079
+100.9%
0.00%
Q3 2018$41,000
-4.7%
537
-2.2%
0.00%
Q2 2018$43,000
+290.9%
549
+155.3%
0.00%
Q1 2018$11,000
-54.2%
215
-59.0%
0.00%
Q4 2017$24,000
+33.3%
525
+51.7%
0.00%
Q3 2017$18,000
-96.9%
346
-96.3%
0.00%
-100.0%
Q2 2017$584,000
-91.5%
9,395
-90.8%
0.00%
-85.7%
Q1 2017$6,887,000
+7726.1%
101,603
+8939.4%
0.01%
Q4 2016$88,000
+203.4%
1,124
+171.5%
0.00%
Q3 2016$29,000
+107.1%
414
+47.3%
0.00%
Q2 2016$14,000
-66.7%
281
-56.5%
0.00%
Q1 2016$42,000
-51.7%
646
-17.4%
0.00%
Q4 2015$87,000
+45.0%
782
+25.9%
0.00%
Q3 2015$60,000
+275.0%
621
+288.1%
0.00%
Q2 2015$16,000
+100.0%
160
-5.9%
0.00%
Q2 2014$8,0001700.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2016
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 519,119$40,605,0003.00%
First Light Asset Management, LLC 236,958$18,535,0002.16%
SECTOR GAMMA AS 108,734$8,505,0001.76%
Rock Springs Capital Management LP 646,841$50,596,0001.39%
Capital Impact Advisors, LLC 30,582$2,392,0000.80%
Atika Capital Management LLC 79,000$6,180,0000.80%
FEDERATED HERMES, INC. 4,080,359$319,166,0000.79%
Rhenman & Partners Asset Management AB 61,500$4,811,0000.52%
Ikarian Capital, LLC 73,500$5,749,0000.46%
Capital International, Inc./CA/ 477,858$37,378,0000.46%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders